Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

Diabetes

Volumn 61, Issue 9, 2012, Pages 2199-2204

  Liu, Jiwen ^a   Lee, TaeWeon ^a   DeFronzo, Ralph A ^b  

^a AMGEN INC   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; GLUCOSE; IPRAGLIFLOZIN; LX 4211; MOLECULE TRANSPORT AGENT; REMOGLIFLOZIN ETABONATE; SODIUM GLUCOSE COTRANSPORTER 2; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; GLUCOSE ABSORPTION; HUMAN; KIDNEY TUBULE EXCRETION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; BLOOD GLUCOSE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY TUBULES, PROXIMAL; MODELS, BIOLOGICAL; PERMEABILITY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84865479822     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0052     Document Type: Review

References (47)

1. Centers for Disease Control and Prevention. 2011. National Diabetes Fact Sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 [Internet]. Atlanta, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Available from www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf. Accessed 11 February 2011
2. DeFronzo RA. Banting lecture. From the triumvirate to the omnious octet: A new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-853, 853-865
4. Brown JB, Conner C, Nichols GA. Secondary failure of metformin monotherapy in clinical practice. Diabetes Care 2010;33:501-506
5. Gerstein HC, Miller ME, Byington RP, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559 (Pubitemid 351831356)
6. Henry RR, Gumbiner B, Ditzler T, Wallace P, Lyon R, Glauber HS. Intensive conventional insulin therapy for type II diabetes: metabolic effects during a 6-month outpatient trial. Diabetes Care 1993;16:21-31 (Pubitemid 23013820)
7. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270-1287
8. Cheung BM, Ong KL, Cherny SS, Sham PC, Tso AWK, Lam KS. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med 2009;122:443-453
9. Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86
10. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-109
11. Farber SJ, Berger EY, Earle DP. Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest 1951;30:125-129
12. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes. Endocr Rev 2011;32:515-531
13. Rossetti L, Shulman GI, Zawalich W, DeFronzo RA. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987;80:1037-1044 (Pubitemid 18075639)
14. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515 (Pubitemid 17099657)
15. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev 2011;91:733-794
16. Vallon V, Platt KA, Cunard R, et al. SGLT2 mediates glucose reabsorption in the early proximal tubule. J Am Soc Nephrol 2011;22:104-112
17. DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab 2012;14:5-14
18. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009;32:1656-1662
19. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab 2010;12:510-516
20. Jones D. Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor. Nat Rev Drug Discov 2011;10:645-646
21. Kipnes MS. Sodium-glucose cotransporter 2 inhibitors in the treatment of Type 2 diabetes: a review of Phase II and III trials. Clin Invest 2011;1:145-156
22. Port A, Macha S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773, a sodium glucose cotransporter-2 (SGLT2) inhibitor, in healthy volunteers. Presented at the 70th Annual Meeting of the American Diabetes Association, 25-29 June 2010, Orlando, Florida
23. Komoroski B, Vachharajani N, Boulton D, et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects. Clin Pharmacol Ther 2009;85:520-526
24. Veltkamp SA, Kadokura T, Krauwinkel WJJ, Smulders RA. Effect of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, on urinary glucose excretion in healthy subjects. Clin Drug Investig 2011;31:839-851
25. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-1800
26. Dugi K, Mark M. Boehringer-Ingelheim R&D press conference [Internet], 17 October 2008. Available from www.boehringer-ingelheim.com/content/.../ slides-mark-dugi.pdf. Accessed 16 April 2011
27. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90
28. Copeland RA, Pompliano DL, Meek TD. Drug-target residence time and its implications for lead optimization. Nat Rev Drug Discov 2006;5:730-739 (Pubitemid 44323700)
29. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos 2010;38:405-414
30. Kalgutkar AS, Tugnait M, Zhu T, et al. Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus. Drug Metab Dispos 2011;39:1609-1619
31. Giacomini KM, Huang SM, Tweedie DJ, et al.; International Transporter Consortium. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-236
32. Feng B, LaPerle JL, Chang G, Varma MV. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opin Drug Metab Toxicol 2010;6:939-952
33. Li M, Anderson GD, Wang J. Drug-drug interactions involving membrane transporters in the human kidney. Expert Opin Drug Metab Toxicol 2006;2:505-532 (Pubitemid 46127070)
34. Varma MV, Feng B, Obach RS, et al. Physicochemical determinants of human renal clearance. J Med Chem 2009;52:4844-4852
35. Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4- ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem 2010;53:3247-3261
36. Schock-Kusch D, Sadick M, Henninger N, et al. Transcutaneous measurement of glomerular filtration rate using FITC-sinistrin in rats. Nephrol Dial Transplant 2009;24:2997-3001
37. Robinson RP, Mascitti V, Boustany-Kari CM, et al. C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization. Bioorg Med Chem Lett 2010;20:1569-1572
38. Mascitti V, Maurer TS, Robinson RP, et al. Discovery of a clinical candidate from the structurally unique dioxa-bicyclo[3.2.1]octane class of sodiumdependent glucose cotransporter 2 inhibitors. J Med Chem2011;54:2952-2960
39. Zhang W, Welihinda A, Mechanic J, et al. EGT1442, a potent and selective SGLT2 inhibitor, attenuates blood glucose and HbA(1c) levels in db/db mice and prolongs the survival of stroke-prone rats. Pharmacol Res 2011;63:284-293
40. Nomura S, Sakamaki S, Hongu M, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem 2010;53:6355-6360
41. Powell D. Oral presentation OR24-6 [article online]. Presented at the Endocrine Society Annual Meeting, 19-22 June 2010, San Diego, California. Available from http://www.lexicon-genetics.com/~lexpha5/images/pdfs/LX4211- ENDO2010-Presentation.pdf. Accessed 21 December 2011
42. Grempler R, Thomas L, Eckhardt M, et al. In Vitro Properties and In Vivo Effect on Urinary Glucose Excretion of BI 10773, a Novel Selective SGLT2 Inhibitor. Presented at the 69th Annual Meeting of the American Diabetes Association, 5-9 June 2009, New Orleans, Louisiana
43. Kapur A, O'Connor-Semmes RL, Hussey EK, et al. First Human Dose Escalation Study with Remogliflozin Etabonate (RE) in Healthy Subjects and in Subjects with Type 2 Diabetes Mellitus (T2DM). Presented at the 69th Annual Meeting of the American Diabetes Association, 5-9 June 2009, New Orleans, Louisiana
44. Wancewicz E, Siwkowski A, Meibohm B, et al. Long term safety and efficacy of ISIS 388626, An optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Presented at the 68th Annual Meeting of the American Diabetes Association, 6-10 June 2008, San Francisco, California
45. Bhanot S, Murray SF, Booten SL, et al. ISIS 388626, an SGLT2 antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well-tolerated (Abstract). Diabetes 2009;58(Suppl. 1):A328
46. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009;32:650-657
47. Freitas HS, D'Agord Schaan B, da Silva RS, Okamoto MM, Oliveira-Souza M, Machado UF. Insulin but not phlorizin treatment induces a transient increase in GLUT2 gene expression in the kidney of diabetic rats. Nephron Physiol 2007;105:p42-p51